Navigation Links
Cobalis Corp. Appoints Martin Marion as Chief Executive Officer
Date:5/13/2010

The Board of Directors of Cobalis Corp announced the appointment of Martin Marion as Chief Executive Officer.

Irvine, CA (PRWEB) May 13, 2010 -- The Board of Directors of Cobalis Corp. (CLSC.PK) announced the appointment of Martin Marion as Chief Executive Officer. Mr. Marion is a seasoned strategic planning and marketing professional with a proven track record of bringing new products to market. Marion will assume responsibility to accelerate the marketing of PreHistin® – the Company’s flagship anti-allergy product – and coordinating various other revenue-generating programs.

Marion was formerly Chief Marketing Officer for Cobalis Corp, from 2003 through 2006, and has extensive knowledge of PreHistin’s competitive advantages. For the past year, Marion has consulted to the Company as Cobalis prepared to launch PreHistin® to the more than 60 million allergy sufferers in the US.
With over a 30 year career in strategic planning and healthcare marketing, Marion has served as Director of Business Development for Grey Advertising / Grey Direct; and VP, Strategic Planning and Business Development for DMB&B’s healthcare division Medicus, then the world’s largest healthcare and pharmaceutical marketing agency. He has consulted to many Tier 1 pharmaceutical marketers with an emphasis on new product introductions and competitive positioning.

Chas Radovich, Cobalis President said: “The appointment of Martin Marion as CEO adds a highly experienced marketing professional to our executive management team, and someone who can assist the Company in achieving its financial goals, with a constant view towards profitability. His extensive healthcare agency and consulting background combined with his first-hand knowledge of PreHistin® enable him to hit the ground running, and immediately commence our marketing launch strategies. We are pleased to welcome Marty back to the Cobalis family as our CEO.”

Marion added: “Cobalis holds tremendous potential, not only for PreHistin® as an entirely new approach to controlling allergies before symptoms arise, but as an innovator and marketer of preventive healthcare products. Our priority now is to quickly build a fundamental and profitable company, engage a team of best-in-class partners to execute our strategies, and thus increase shareholder value. We understand the challenges that lie ahead and our team is prepared to make the smart decisions necessary to successfully bring PreHistin® to market in the US and internationally.”

ABOUT COBALIS CORP—PREHISTIN®
Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin®, The World’s FIRST Pre-Histamine”™, is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is available without prescription for both long-term and daily use.
For PreHistin® product information and ordering please visit at www.PreHistin.com or call toll free
1-877-4POLLEN. For additional company information please visit the corporate website at www.Cobalis.com.

CONTACT
Cobalis Corp.
2030 Main St., Suite 1300
Irvine, CA 92614
949-260-9007
Chas Radovich, President
Martin Marion, CEO
info (at) cobalis (dot) com
info (at) prehistin (dot) com

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb3996694.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
4. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
7. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
8. Helix BioPharma Corp. announces fiscal 2007 results
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
10. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
11. Helix BioPharma Corp. announces management changes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cobalis Corp. Appoints Martin Marion as Chief Executive Officer  
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
(Date:2/23/2017)... ... 23, 2017 , ... Today, researchers can fast-track sample collection ... and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With ... relationship between insulin and other relevant biomarkers can be extensively studied through a ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
Breaking Biology Technology:
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
Breaking Biology News(10 mins):